Chemed (CHE) is down about 3% as the market refocuses on weaker profitability trends at Roto-Rooter and the uncertainty created by management’s discussion of potential divestiture options for the plumbing business. The pullback comes even after Chemed lifted its 2026 adjusted EPS guidance range to $24.00–$24.75, implying that investors are treating the segment split and margin trajectory as the dominant near-term catalyst rather than the consolidated guidance raise. (stocktitan.net)

In the Q1 2026 update, Chemed disclosed that Roto-Rooter revenue slipped year over year and adjusted EBITDA fell, with margin down to 22.5%. The company also trimmed its full-year Roto-Rooter adjusted EBITDA margin outlook to 21.5%–22.5%, citing elevated marketing costs alongside other operational headwinds—exactly the type of detail that can pressure a defensive healthcare/services name’s multiple when investors are paying for stability. (stocktitan.net)

Chemed’s hospice business VITAS continued to post growth, supporting the company’s decision to raise full-year 2026 adjusted EPS guidance. The quarter also featured significant capital deployment, including repurchasing 500,000 shares for $197.7 million and acquiring two Roto-Rooter franchises for $20.6 million, which can help support per-share results even as Roto-Rooter margins face pressure. (stocktitan.net)

The market reaction suggests investors are weighing whether Roto-Rooter is becoming a structurally lower-margin business due to marketing dynamics, and whether a divestiture process could introduce execution risk, timing uncertainty, and changing earnings mix. With the earnings release and presentation arriving in late April (Q1 2026 results), CHE’s move looks like a post-earnings re-rating and positioning shift rather than a single headline shock. (au.investing.com)